I-MAB

0VY

Company Profile

  • Business description

    I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People’s Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).

  • Contact

    2440 Research Boulevard
    Suite 400
    RockvilleMD20850
    USA

    T: +1 240 745-6330

    https://www.i-mabbiopharma.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    32

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,462.6040.900.49%
CAC 407,743.7549.310.64%
DAX 4023,499.32146.630.63%
Dow JONES (US)41,249.38119.07-0.29%
FTSE 1008,554.8023.190.27%
HKSE22,867.7491.820.40%
NASDAQ17,928.920.780.00%
Nikkei 22537,503.33574.701.56%
NZX 50 Index12,605.07138.041.11%
S&P 5005,659.914.03-0.07%
S&P/ASX 2008,231.2039.500.48%
SSE Composite Index3,342.0010.00-0.30%

Market Movers